Treatment outcomes after initiation of exenatide twice daily or insulin in clinical practice: 12-month results from CHOICE in six European countries.

Also, there may be significant unmeasured confounding factors we were unable to control for in the subgroup comparison of cohorts, and we used non-standardized measurements to assess clinical outcomes, including hypoglycemia, which relied on patient recall and self-reporting of episodes that did not have standardized diagnoses.

also in 13,097 other papers